Targeting NF-kB Signaling using a Novel Inhibitor in DLBCL

Title

Targeting NF-kB Signaling using a Novel Inhibitor in DLBCL

Files

Download Julia Ceniceros Original Presentation File (197 KB)

Loading...

Media is loading
 

Publication Date

Summer 8-6-2020

College, Institute, or Department

Eppley Institute for Research in Cancer

Faculty Mentor

Dalia Elgamal

Research Mentor

Alexandria Eiken

Document Type

Poster

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy that can be categorized by cell of origin, molecular features and reoccurring mutations. The transcription factor “NF-κB” plays a key role in cell survival, inflammation and immune responses; in cancer it promotes malignant cell proliferation.Targeting pathways such as the NF-κB is a viable option to treat B-cell malignancies. A novel NF-κB inhibitor was evaluated in DLBCL cell lines (OCI-LY3, RI-1, and Pfeiffer). The NF-κB inhibitor showed cytotoxic effects in DLBCL cells, especially those dependent on NF-κB.

Keywords

NF-kB Novel Inhibitor DLBCL

Targeting NF-kB Signaling using a Novel Inhibitor in DLBCL

Share

COinS